Log in  First Connection?

Kidney TransplantationArchives

Neuropsychological Profile in Older Adults with End-Stage Kidney Disease during Kidney Transplantation Evaluation

 Published on 01/04/2026 |  Original article (Full-text)  | Elodie Pongan et al. | Archives of clinical neuropsychology. Volume 40(4).

End-stage chronic kidney disease (CKD) is a significant concern for older adults and is often associated with cognitive impairment (CI). The origin of this CI is multifactorial, involving vascular and metabolic factors. Additionally, renal treatments, including dialysis, may affect cognition. This study...

HLA and non-HLA antibody profiling in the urine of kidney transplant recipients

 Published on 25/03/2026 |  Original article (Full-text)  | Tara K. Sigdel et al. | Expert Review of Proteomics 2025; 22(11-12): 569-577

Kidney transplantation is the preferred therapy for end-stage renal disease (ESRD), yet long-term graft survival remains limited. Effective preservation of transplanted kidneys is essential amid a persistent organ shortage. Post-transplant graft injury arises from both immune and nonimmune mechanisms....

Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: Results of a Randomized Controlled Trial

 Published on 18/03/2026 |  Original article (Full-text)  | A Lianne Messchendorp et al. | Clinical infectious diseases. Volume 81(6).

Vaccine immunogenicity is reduced in kidney transplant recipients (KTRs), especially in those using mycophenolate mofetil (MMF). Whether replacement of MMF by everolimus improves vaccine immunogenicity is unknown. Methods: KTRs were randomized 1:1 to continue MMF or switch to everolimus. Participants...

Intravenous trimethoprim–sulfamethoxazole desensitization as a therapeutic strategy for late-onset Pneumocystis jirovecii pneumonia in a kidney transplant recipient: a case report

 Published on 11/03/2026 |  Original article (Full-text)  | Yılmaz Banu | Journal of Medical Case Reports 2025; 20(1): 117

Kidney transplantation is the most effective treatment option for end-stage renal disease. However, chronic antibody-mediated rejection (cAMR) remains one of the major causes limiting long-term graft survival [1]. High-dose corticosteroids, intravenous immunoglobulin (IVIG), and rituximab are frequently...